BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. American Heart Journal 2015;170:141-148.e1. [DOI: 10.1016/j.ahj.2015.03.017] [Cited by in Crossref: 130] [Cited by in F6Publishing: 115] [Article Influence: 18.6] [Reference Citation Analysis]
Number Citing Articles
1 Baumgartner C, Fan D, Fang MC, Singer DE, Witt DM, Schmelzer JR, Williams MS, Gurwitz JH, Sung SH, Go AS. Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. J Am Heart Assoc 2018;7:e007814. [PMID: 29656278 DOI: 10.1161/JAHA.117.007814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Qiu S, Wang N, Zhang C, Gu ZC, Qian Y. Anticoagulation Quality of Warfarin and the Role of Physician-Pharmacist Collaborative Clinics in the Treatment of Patients Receiving Warfarin: A Retrospective, Observational, Single-Center Study. Front Pharmacol 2020;11:605353. [PMID: 33519468 DOI: 10.3389/fphar.2020.605353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Reiffel JA. Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum. J Innov Card Rhythm Manag 2017;8:2643-6. [PMID: 32494441 DOI: 10.19102/icrm.2017.080302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.Medicina (Kaunas). 2019;55. [PMID: 30650565 DOI: 10.3390/medicina55010015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Semakula JR, Kisa G, Mouton JP, Cohen K, Blockman M, Pirmohamed M, Sekaggya-Wiltshire C, Waitt C. Anticoagulation in sub-Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. Br J Clin Pharmacol 2021. [PMID: 33624331 DOI: 10.1111/bcp.14796] [Reference Citation Analysis]
6 Chan NC, Eikelboom JW, Weitz JI. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. Circ Res. 2016;118:1409-1424. [PMID: 27126650 DOI: 10.1161/circresaha.116.306925] [Cited by in Crossref: 68] [Cited by in F6Publishing: 22] [Article Influence: 13.6] [Reference Citation Analysis]
7 Chaudhary R, Sharma T, Garg J, Sukhi A, Bliden K, Tantry U, Turagam M, Lakkireddy D, Gurbel P. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis 2020;49:271-86. [PMID: 31512202 DOI: 10.1007/s11239-019-01954-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 11.5] [Reference Citation Analysis]
8 Gotsman I, Ezra O, Hirsh Raccah B, Admon D, Lotan C, Dekeyser Ganz F. Patient-Specific Tailored Intervention Improves INR Time in Therapeutic Range and INR Variability in Heart Failure Patients. The American Journal of Medicine 2017;130:982-9. [DOI: 10.1016/j.amjmed.2017.02.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
9 Lim HY, Ho P. Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population. Dent J (Basel) 2016;4:E7. [PMID: 29563449 DOI: 10.3390/dj4010007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Charles PY, Le Meur Y, Tanquerel T, Galinat H. Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients. Clin Kidney J 2020;13:647-53. [PMID: 32905339 DOI: 10.1093/ckj/sfz131] [Reference Citation Analysis]
11 Zhu Y, Xu C, Liu J. Randomized controlled trial of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation. J Clin Pharm Ther 2020;45:1466-73. [PMID: 32710457 DOI: 10.1111/jcpt.13218] [Reference Citation Analysis]
12 Silva PGMBE, Sznejder H, Vasconcellos R, Charles GM, Mendonca-Filho HTF, Mardekian J, Nascimento R, Dukacz S, Fusco MD. Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study. Arq Bras Cardiol 2020;114:457-66. [PMID: 32049154 DOI: 10.36660/abc.20180076] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Boswell R, Pearson GJ. A review of the use of direct oral anticoagulant use in orthotopic heart transplantation recipients. Transplantation Reviews 2018;32:151-6. [DOI: 10.1016/j.trre.2018.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Westerman S, Wenger N. Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes. Curr Cardiol Rev 2019;15:136-44. [PMID: 30516110 DOI: 10.2174/1573403X15666181205110624] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
15 Proietti M, Lip GY. Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. International Journal of Cardiology 2017;236:244-8. [DOI: 10.1016/j.ijcard.2017.02.127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Essien UR, Holmes DN, Jackson LR 2nd, Fonarow GC, Mahaffey KW, Reiffel JA, Steinberg BA, Allen LA, Chan PS, Freeman JV, Blanco RG, Pieper KS, Piccini JP, Peterson ED, Singer DE. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol 2018;3:1174-82. [PMID: 30484833 DOI: 10.1001/jamacardio.2018.3945] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
17 Shields LBE, Fowler P, Siemens DM, Lorenz DJ, Wilson KC, Hester ST, Honaker JT. Standardized warfarin monitoring decreases adverse drug reactions.BMC Fam Pract. 2019;20:151. [PMID: 31699045 DOI: 10.1186/s12875-019-1041-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Singh M, Sporn ZA, Schaff HV, Pellikka PA. ACC/AHA Versus ESC Guidelines on Prosthetic Heart Valve Management. Journal of the American College of Cardiology 2019;73:1707-18. [DOI: 10.1016/j.jacc.2019.01.038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
19 Beyene K, Chan AHY, Näslund P, Harrison J. Patient-related factors associated with oral anticoagulation control: a population-based cohort study. Int J Pharm Pract 2021:riab041. [PMID: 34302345 DOI: 10.1093/ijpp/riab041] [Reference Citation Analysis]
20 Anouti K, Kowey PR. Assessing intracardiac thrombus prior to cardioversion: A story yet to be told. J Cardiovasc Electrophysiol 2018;29:548-50. [PMID: 29437262 DOI: 10.1111/jce.13462] [Reference Citation Analysis]
21 Wu VC, Huang YC, Chen SW, Liu CH, Chang CW, Chen CC, Chang SH, Lin MS, Lee TH, Chen MC, Hsieh IC, Chu PH, Lin YS. Resuming anticoagulation in patients with atrial fibrillation experiencing intracranial hemorrhage. Medicine (Baltimore) 2021;100:e26945. [PMID: 34397946 DOI: 10.1097/MD.0000000000026945] [Reference Citation Analysis]
22 Boonyawat K, Wang L, Lazo-Langner A, Kovacs MJ, Yeo E, Schnurr T, Schulman S, Crowther MA. The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. Thromb Haemost 2016;116:480-5. [PMID: 27346552 DOI: 10.1160/TH16-04-0320] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Kostopoulou A, Zeljko HM, Bogossian H, Ciudin R, Costa F, Heijman J, Kochhaeuser S, Manola S, Scherr D, Sohal M, Wakili R, Wolf M, Irfan G; on the behalf of the DAS-CAM participants-2017-2018. Atrial fibrillation-related stroke in women: Evidence and inequalities in epidemiology, mechanisms, clinical presentation, and management. Clin Cardiol 2020;43:14-23. [PMID: 31691981 DOI: 10.1002/clc.23284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Chao TF, Hong KS, Lee BC, De Caterina R, Kirchhof P, Reimitz PE, Chen C, Unverdorben M, Wang CC. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. J Chin Med Assoc 2021;84:485-90. [PMID: 33742992 DOI: 10.1097/JCMA.0000000000000516] [Reference Citation Analysis]
25 Bernaitis N, Ching CK, Badrick T, Anoopkumar-Dukie S. Identifying Warfarin Control With Stroke and Bleed Risk Scores. Heart Lung Circ 2018;27:756-9. [PMID: 29233496 DOI: 10.1016/j.hlc.2017.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
26 Cox JL, Parkash R, Abidi SS, Thabane L, Xie F, Mackillop J, Abidi SR, Ciaccia A, Choudhri SH, Abusharekh A, Nemis-white J. Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. American Heart Journal 2018;201:149-57. [DOI: 10.1016/j.ahj.2018.04.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
27 Albabtain MA, Alharthi MM, Dagriri K, Arafat AA, Ayrout E, Alhebaishi Y, AlFagih A. Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. Saudi Med J 2020;41:1245-51. [PMID: 33130846 DOI: 10.15537/smj.2020.11.25456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Yuce H, Keshishian A. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PLoS One 2019;14:e0213614. [PMID: 30908512 DOI: 10.1371/journal.pone.0213614] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
29 Fanikos J, Burnett AE, Mahan CE, Dobesh PP. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. The American Journal of Medicine 2017;130:1015-23. [DOI: 10.1016/j.amjmed.2017.04.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
30 Al Rawahi M, Samuel M, Galatas C, Joza J, Lima PY, Barbosa R, Thanassoulis G, Bernier ML, Huynh T, Essebag V. Incidence and Predictors of Intracardiac Thrombus on Pre-electrophysiological Procedure Transesophageal Echocardiography. CJC Open 2019;1:231-7. [PMID: 32159114 DOI: 10.1016/j.cjco.2019.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Proietti M, Lane DA, Lip GYH. Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. EBioMedicine 2016;8:309-16. [PMID: 27428440 DOI: 10.1016/j.ebiom.2016.04.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
32 Powers A, Loesch EB, Weiland A, Fioravanti N, Lucius D. Preemptive warfarin dose reduction after initiation of sulfamethoxazole-trimethoprim or metronidazole. J Thromb Thrombolysis 2017;44:88-93. [PMID: 28417267 DOI: 10.1007/s11239-017-1497-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
33 Pokorney SD, Black-maier E, Hellkamp AS, Friedman DJ, Vemulapalli S, Granger CB, Thomas L, Peterson ED, Piccini JP. Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. Journal of the American College of Cardiology 2020;75:1299-308. [DOI: 10.1016/j.jacc.2020.01.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
34 Peterson ED, Pokorney SD. New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation ∗. Journal of the American College of Cardiology 2017;69:2485-7. [DOI: 10.1016/j.jacc.2017.03.541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 da Silveira MMBM, Melo LA, Gomes FMF, Andrade LJCBDR, Serur IP, Piscoya ICV, Gueiros RM, Palmeira do Ó K, de Lima RE, Brasileiro VAE, Vasconcelos LRS, Sobral Filho DC. Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin. Appl Clin Genet 2019;12:151-9. [PMID: 31447576 DOI: 10.2147/TACG.S197316] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
36 Liang X, Xie W, Lin Z, Liu M. The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis. Anatol J Cardiol 2021;25:77-88. [PMID: 33583814 DOI: 10.14744/AnatolJCardiol.2020.18049] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Pokorney SD, Peterson ED, Piccini JP. When Less Is Not More ∗. Journal of the American College of Cardiology 2017;69:2791-3. [DOI: 10.1016/j.jacc.2017.04.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
38 Polo García J, Barrios Alonso V, Escobar Cervantes C, Prieto Valiente L, Lobos Bejarano J, Vargas Ortega D, Prieto Díaz M, Alonso Moreno F, Barquilla García A. Control de la anticoagulación en pacientes con fibrilación auricular no valvular en práctica clínica de atención primaria en las diferentes comunidades autónomas. Estudio PAULA. SEMERGEN - Medicina de Familia 2017;43:207-15. [DOI: 10.1016/j.semerg.2016.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
39 Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Mahaffey KW, Nessel CC, Singer DE, Patel MR. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016;134:37-47. [DOI: 10.1161/circulationaha.116.021890] [Cited by in Crossref: 92] [Cited by in F6Publishing: 24] [Article Influence: 15.3] [Reference Citation Analysis]
40 Karas TZ, Accola KD. Commentary: Anticoagulation strategies: Awaiting a new paradigm. J Thorac Cardiovasc Surg 2021:S0022-5223(21)01044-8. [PMID: 34340849 DOI: 10.1016/j.jtcvs.2021.07.013] [Reference Citation Analysis]
41 Lin SY, Chen YW, Kang HC, Wu YJ, Chen PZ, Wu CW, Lin CS, Wu FL, Shen LJ, Huang YM, Huang CF. Effects of a pharmacist-managed anticoagulation outpatient clinic in Taiwan: evaluation of patient knowledge, satisfaction, and clinical outcomes. Postgrad Med 2021;:1-10. [PMID: 34180349 DOI: 10.1080/00325481.2021.1949212] [Reference Citation Analysis]
42 Lunde ED, Nielsen PB, Riahi S, Larsen TB, Lip GY, Fonager K, Larsen ML, Joensen AM. Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. Expert Review of Cardiovascular Therapy 2018;16:857-73. [DOI: 10.1080/14779072.2018.1533118] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
43 Riva N, Borg Xuereb C, Ageno W, Makris M, Gatt A. Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS). Psychol Res Behav Manag 2019;12:741-52. [PMID: 31695528 DOI: 10.2147/PRBM.S216617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Botton MR, Viola PP, Meireles MR, Bruxel EM, Zuchinali P, Bandinelli E, Rohde LE, Leiria TLL, Salamoni JYY, Garbin AP, Hutz MH. Identification of environmental and genetic factors that influence warfarin time in therapeutic range. Genet Mol Biol 2020;43:e20190025. [PMID: 32052826 DOI: 10.1590/1678-4685-GMB-2019-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Masjuan J, Defelipe A. Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban. International Journal of Neuroscience 2016;127:716-25. [DOI: 10.1080/00207454.2016.1232256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Bashir B, Stickle DF, Chervoneva I, Kraft WK. Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers. Clin Transl Sci 2018;11:590-6. [PMID: 29972633 DOI: 10.1111/cts.12580] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
47 Madan S, Shah S, Dale P, Partovi S, Parikh SA. Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther 2016;6:570-81. [PMID: 28123977 DOI: 10.21037/cdt.2016.11.17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
48 Weinberger J, Cipolle M. Optimal Reversal of Novel Anticoagulants in Trauma. Crit Care Clin 2017;33:135-52. [PMID: 27894493 DOI: 10.1016/j.ccc.2016.08.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
49 Williams BA, Evans MA, Honushefsky AM, Berger PB. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation. J Am Heart Assoc 2017;6:e006669. [PMID: 29025746 DOI: 10.1161/JAHA.117.006669] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Huda SA, Kahlown S, Jilani MH, Chaudhuri D. Management of Life-Threatening Bleeding in Patients With Mechanical Heart Valves. Cureus 2021;13:e15619. [PMID: 34277237 DOI: 10.7759/cureus.15619] [Reference Citation Analysis]
51 Çelik A, İzci S, Kobat MA, Ateş AH, Çakmak A, Çakıllı Y, Yılmaz MB, Zoghi M; WARFARIN-TR Study Collaborates. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol 2016;16:595-600. [PMID: 27004711 DOI: 10.5152/AnatolJCardiol.2015.6474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
52 Ponamgi SP, Siontis KC, Rushlow DR, Graff-Radford J, Montori V, Noseworthy PA. Screening and management of atrial fibrillation in primary care. BMJ. 2021;373:n379. [PMID: 33846159 DOI: 10.1136/bmj.n379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Evans CE, Getchell KE, Ivy DR. Proposed Criteria for the Use of Low-Dose Vitamin K Supplementation in Patients Using Vitamin K Antagonists: A Literature Review of a Clinical Controversy. Journal of Pharmacy Practice 2018;31:208-15. [DOI: 10.1177/0897190017711518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant 2018;18:907-15. [PMID: 28925597 DOI: 10.1111/ajt.14504] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 11.4] [Reference Citation Analysis]
55 Harris DE, Thayer D, Wang T, Brooks C, Murley G, Gravenor M, Hill NR, Lister S, Halcox J. An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS). Eur Heart J Cardiovasc Pharmacother 2021;7:40-9. [PMID: 31774502 DOI: 10.1093/ehjcvp/pvz071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
56 Geurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, Reiffel JA, Singer DE, Freeman J, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli G, Piccini JP, Peterson ED, Pokorney SD. Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart 2021;107:642-9. [PMID: 32591363 DOI: 10.1136/heartjnl-2019-316315] [Reference Citation Analysis]
57 Voskamp PWM, Rookmaaker MB, Verhaar MC, Dekker FW, Ocak G. Vitamin K antagonist use and mortality in dialysis patients. Nephrology Dialysis Transplantation 2018;33:170-6. [DOI: 10.1093/ndt/gfx199] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
58 Liberato NL, Marchetti M. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. Expert Review of Pharmacoeconomics & Outcomes Research 2016;16:221-35. [DOI: 10.1586/14737167.2016.1147351] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
59 Diken Aİ, Yalçınkaya A, Hanedan MO, Erol ME, Ercen Diken Ö. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis. Phlebology 2018;33:53-9. [DOI: 10.1177/0268355516688358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Chapin TW, Leedahl DD, Brown AB, Pasek AM, Sand MG, Loy ML, Dyke CM. Comparison of Anticoagulants for Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Pilot Study. J Cardiovasc Pharmacol Ther 2020;25:523-30. [PMID: 32476465 DOI: 10.1177/1074248420929483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
61 Uphaus T, Singer OC, Berkefeld J, Nolte CH, Bohner G, Niederkorn K, Deutschmann H, Haring H, Trenkler J, Neumann-haefelin T, Hofmann E, Stoll A, Bormann A, Bussmeyer M, Mpotsaris A, Reich A, Wiesmann M, Petzold GC, Urbach H, Jander S, Turowski B, Weimar C, Schlamann M, Liebeskind DS, Gröschel S, Boor S, Gröschel K. Safety of endovascular treatment in acute stroke patients taking oral anticoagulants. International Journal of Stroke 2017;12:412-5. [DOI: 10.1177/1747493016677986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
62 MacIsaac S, Jaffer IH, Belley-Côté EP, McClure GR, Eikelboom JW, Whitlock RP. How Did We Get Here?: A Historical Review and Critical Analysis of Anticoagulation Therapy Following Mechanical Valve Replacement. Circulation 2019;140:1933-42. [PMID: 31790297 DOI: 10.1161/CIRCULATIONAHA.119.041105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
63 Whitlock RP, Fordyce CB, Midei MG, Ellis D, Garcia D, Weitz JI, Canafax DM, Albrecht D, Milner PG. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin: The EmbraceAC Trial. Thromb Haemost 2018;116:241-50. [DOI: 10.1160/th15-11-0910] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
64 Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, Go AS, Kaiser DW, Hylek EM, Kowey PR, Singer DE, Thomas L, Steinberg BA, Peterson ED, Piccini JP, Mahaffey KW. Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. J Am Heart Assoc 2019;8:e011205. [PMID: 31023126 DOI: 10.1161/JAHA.118.011205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
65 Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FW, Wildgoose P, van Eickels M, Lip GY, Cohen M, Fox KA, Gibson CM. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.118.007124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
66 Shah BR, Scholtus E, Rolland C, Batscheider A, Katz JN, Nilsson KR Jr. A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation. Curr Med Res Opin 2019;35:127-39. [PMID: 30380959 DOI: 10.1080/03007995.2018.1543184] [Reference Citation Analysis]
67 Marín F, Anguita-Sánchez M, Sanmartín M. Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation. Expert Opin Pharmacother 2017;18:67-77. [PMID: 27924633 DOI: 10.1080/14656566.2016.1267140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
68 McAuliffe GN, De Silva F, Upton A, Chan G. International normalised ratio monitoring in the community populations of the Auckland and Northland regions of New Zealand: time in therapeutic range and frequency of testing. Intern Med J 2018;48:1487-91. [PMID: 29992735 DOI: 10.1111/imj.14032] [Reference Citation Analysis]
69 Martinez BK, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. ESC Heart Fail 2019;6:10-5. [PMID: 30299591 DOI: 10.1002/ehf2.12365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
70 Liu S, Li X, Shi Q, Hamilton M, Friend K, Zhao Y, Horblyuk R, Hede S, Shi L. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation. Current Medical Research and Opinion 2018;34:415-21. [DOI: 10.1080/03007995.2017.1384370] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
71 Goldstein LN, Wu MT. A one year audit of patients with venous thromboembolism presenting to a tertiary hospital in Johannesburg, South Africa. Afr J Emerg Med 2018;8:12-5. [PMID: 30456139 DOI: 10.1016/j.afjem.2017.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
72 Barrios V, Escobar C. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. Future Cardiology 2016;12:419-33. [DOI: 10.2217/fca-2016-0021] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
73 Nathan AS, Geng Z, Dayoub EJ, Khatana SAM, Eberly LA, Kobayashi T, Pugliese SC, Adusumalli S, Giri J, Groeneveld PW. Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United States. Circ: Cardiovascular Quality and Outcomes 2019;12. [DOI: 10.1161/circoutcomes.119.005600] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
74 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
75 Mtwesi V, Amit G. Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation. Med Clin North Am 2019;103:847-62. [PMID: 31378330 DOI: 10.1016/j.mcna.2019.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
76 Gurevich S, Oestreich B, Kelly RF, Mbai M, Bertog S, Yannopoulos D, Garcia S. Routine use of anticoagulation after transcatheter aortic valve replacement: Initial safety outcomes from a single-center experience. Cardiovasc Revasc Med 2018;19:621-5. [PMID: 29276174 DOI: 10.1016/j.carrev.2017.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
77 Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Lip GYH, Marín F. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Sci Rep 2017;7:12066. [PMID: 28935868 DOI: 10.1038/s41598-017-11683-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
78 Madhavan M, Holmes DN, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Chan P, Allen LA, Gersh BJ; ORBIT AF Investigators. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am Heart J 2019;211:77-89. [PMID: 30901602 DOI: 10.1016/j.ahj.2019.01.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
79 Woldendorp K, Khadra S, Bannon PG, Robinson BM. Novel Oral Anticoagulants Compared to Warfarin for Postoperative Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting. Heart Lung Circ 2020;29:1832-8. [PMID: 32622911 DOI: 10.1016/j.hlc.2020.04.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
80 Dobesh PP, Fanikos J. Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others? J Atr Fibrillation 2016;9:1481. [PMID: 27909544 DOI: 10.4022/jafib.1481] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
81 Hellyer JA, Azarbal F, Than CT, Fan J, Schmitt SK, Yang F, Frayne SM, Phibbs CS, Yong C, Heidenreich PA, Turakhia MP. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study). Am J Cardiol 2017;119:268-74. [PMID: 27836133 DOI: 10.1016/j.amjcard.2016.09.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
82 Barrios V, Masjuan J. Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile. Future Cardiol 2017;13:49-64. [PMID: 27731650 DOI: 10.2217/fca-2016-0061] [Reference Citation Analysis]
83 Lip GY, Al-saady N, Ezekowitz MD, Banach M, Goette A. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. American Heart Journal 2017;193:16-22. [DOI: 10.1016/j.ahj.2017.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
84 Eggebrecht L, Ludolph P, Göbel S, Panova-Noeva M, Arnold N, Nagler M, Bickel C, Lauterbach M, Hardt R, Cate HT, Lackner KJ, Espinola-Klein C, Münzel T, Prochaska JH, Wild PS. Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study. Sci Rep 2021;11:2577. [PMID: 33510343 DOI: 10.1038/s41598-021-82076-9] [Reference Citation Analysis]
85 Meredith T, Schnegg B, Hayward C. The use of direct oral anticoagulants in patients with ventricular assist devices: Is there hope for Factor Xa inhibition? Artif Organs 2021;45:E123-9. [PMID: 33084087 DOI: 10.1111/aor.13848] [Reference Citation Analysis]
86 Wang N, Qiu S, Yang Y, Zhang C, Gu ZC, Qian Y. Physician-Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development. Front Pharmacol 2021;12:673302. [PMID: 34177585 DOI: 10.3389/fphar.2021.673302] [Reference Citation Analysis]
87 Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Marín F, Lip GYH. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clin Ther 2018;40:114-22. [PMID: 29275065 DOI: 10.1016/j.clinthera.2017.11.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
88 Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F, Lassila R, Raatikainen P. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry: Quality of Warfarin Therapy. Pharmacoepidemiol Drug Saf 2017;26:657-65. [DOI: 10.1002/pds.4194] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
89 Pokorney SD, Gersh BJ, Ahmad A, Al-khatib SM, Blank M, Coylewright M, Dibattiste P, Healey JS, Hedrich O, Hylek EM, Kline-rogers E, Peterson ED, Mendys P, Mirro MJ, Naccarelli G, Patel P, Ruff CT, Rutman H, Stockbridge N, Temple R, Granger CB. Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal 2019;210:29-38. [DOI: 10.1016/j.ahj.2018.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
90 Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GY, Nordaby M, Kleine E, ten Berg JM, Bhatt DL, Cannon CP. Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. JACC: Cardiovascular Interventions 2019;12:1553-61. [DOI: 10.1016/j.jcin.2019.05.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
91 Wang K, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang C, Giugliano RP. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. European Heart Journal 2019;40:1492-500. [DOI: 10.1093/eurheartj/ehy802] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
92 Odashiro K, Yokoyama T, Fukata M, Arita T, Maruyama T, Akashi K. Anticoagulation Stability Depends on CHADS2 Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation. J Atheroscler Thromb 2017;24:68-76. [PMID: 27319745 DOI: 10.5551/jat.35121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
93 Marcatto LR, Sacilotto L, Tavares LC, Facin M, Olivetti N, Strunz CMC, Darrieux FCC, Scanavacca MI, Krieger JE, Pereira AC, Santos PCJL. Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin. Front Pharmacol 2018;9:1052. [PMID: 30298004 DOI: 10.3389/fphar.2018.01052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
94 Ferreira JL, Wipf JE. Pharmacologic Therapies in Anticoagulation. Med Clin North Am 2016;100:695-718. [PMID: 27235611 DOI: 10.1016/j.mcna.2016.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
95 Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother 2021:pvab018. [PMID: 33638977 DOI: 10.1093/ehjcvp/pvab018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Sur NB, Saini V, Torres LF, Atchaneeyasakul K, Malik AM, Yavagal DR, Chaturvedi S. The Proportion of Preventable Thrombectomy Procedures with Improved Atrial Fibrillation Stroke Prevention. J Stroke Cerebrovasc Dis 2021;30:105599. [PMID: 33545519 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105599] [Reference Citation Analysis]
97 Contreras Muruaga MM, Reig G, Vivancos J, González A, Cardona P, Ramírez-Moreno JM, Martí-Fábregas J, Suárez Fernández C; en nombre de los investigadores del estudio ALADIN., Listado de investigadores del estudio ALADIN. Factors associated with poor anticoagulation control with vitaminK antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study. Rev Clin Esp (Barc) 2018;218:327-35. [PMID: 29983190 DOI: 10.1016/j.rce.2018.04.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
98 Knežević A, Nadinić M, Užović Frakin I, Trkulja V. Poor warfarin anticoagulation in long-term thromboprophylaxis: a survey in a southern Croatian county. Croat Med J 2019;60:2-11. [PMID: 30825272 [PMID: 30825272 DOI: 10.3325/cmj.2019.60.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
99 Elango K, Javaid A, Khetarpal BK, Ramalingam S, Kolandaivel KP, Gunasekaran K, Ahsan C. The Effects of Warfarin and Direct Oral Anticoagulants on Systemic Vascular Calcification: A Review. Cells 2021;10:773. [PMID: 33807457 DOI: 10.3390/cells10040773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Kai B, Bogorad Y, Nguyen LN, Yang S, Chen W, Spencer HT, Shen AY, Lee M. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. Heart Rhythm 2017;14:645-51. [DOI: 10.1016/j.hrthm.2017.01.047] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
101 Yang F, Hellyer JA, Than C, Ullal AJ, Kaiser DW, Heidenreich PA, Hoang DD, Winkelmayer WC, Schmitt S, Frayne SM, Phibbs CS, Turakhia MP. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 2017;103:818-26. [PMID: 27852694 DOI: 10.1136/heartjnl-2016-309266] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
102 Roldan T, Villamañán E, Rios JJ, Waxman AB. Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension. Thrombosis Research 2017;160:83-90. [DOI: 10.1016/j.thromres.2017.10.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
103 McAlister FA, Wiebe N, Hemmelgarn BR. Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada.BMJ Open. 2018;8:e016980. [PMID: 29382672 DOI: 10.1136/bmjopen-2017-016980] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
104 Hospodar AR, Smith KJ, Zhang Y, Hernandez I. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. Am J Cardiovasc Drugs 2018;18:317-25. [PMID: 29740750 DOI: 10.1007/s40256-018-0279-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
105 Kurlander JE, Barnes GD, Anderson MA, Haymart B, Kline-Rogers E, Kaatz S, Saini SD, Krein SL, Richardson CR, Froehlich JB. Mind the gap: results of a multispecialty survey on coordination of care for peri-procedural anticoagulation. J Thromb Thrombolysis 2018;45:403-9. [PMID: 29423559 DOI: 10.1007/s11239-018-1625-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
106 Djalali S, Valeri F, Gerber B, Meli DN, Senn O. Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clin Appl Thromb Hemost 2017;23:685-95. [PMID: 27056934 DOI: 10.1177/1076029616642514] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
107 Reilly RF, Jain N. Warfarin in nonvalvular atrial fibrillation-Time for a change? Semin Dial 2019;32:520-6. [PMID: 31209952 DOI: 10.1111/sdi.12829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Ko D, Rahman F, Martins MA, Hylek EM, Ellinor PT, Schnabel RB, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: treatment. Nat Rev Cardiol 2017;14:113-24. [PMID: 27786235 DOI: 10.1038/nrcardio.2016.171] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
109 Raatikainen MJP, Penttilä T, Korhonen P, Mehtälä J, Lassila R, Lehto M. The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry. Eur Heart J Cardiovasc Pharmacother 2018;4:211-9. [PMID: 29514184 DOI: 10.1093/ehjcvp/pvy009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
110 Daugherty J, Heyrend C, Profsky M, Kay B, VanderPluym C, Griffiths ER, May LJ. Time in Therapeutic Range for Bivalirudin Among Pediatric Ventricular Assist Device Recipients. ASAIO J 2021;67:588-93. [PMID: 32826396 DOI: 10.1097/MAT.0000000000001261] [Reference Citation Analysis]
111 Valdelièvre E, Quéré I, Caré B, Laroche J, Schved J. Utilité du TTR (temps passé dans la cible thérapeutique) dans le suivi des patients sous antivitamine K : analyse d’une cohorte de patients. JMV-Journal de Médecine Vasculaire 2018;43:155-62. [DOI: 10.1016/j.jdmv.2018.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Escobar C, Barrios V, Prieto L. Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled. European Journal of Internal Medicine 2016;30:e17-8. [DOI: 10.1016/j.ejim.2016.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
113 Potpara TS, Dagres N, Mujović N, Vasić D, Ašanin M, Nedeljkovic M, Marin F, Fauchier L, Blomstrom-Lundqvist C, Lip GY. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. Adv Ther 2017;34:357-77. [PMID: 27933569 DOI: 10.1007/s12325-016-0458-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
114 Avarello I, Bianchi S, Toschi V, Zighetti ML, Faioni EM. Time in therapeutic range is lower in women than in men and is not explained by differences in age or comorbidity. Thromb Res 2021;203:18-21. [PMID: 33901765 DOI: 10.1016/j.thromres.2021.04.011] [Reference Citation Analysis]
115 Galli F, Borghi L, Faioni E, Cavicchioli M, Ferrari Losi J, Vegni E. Failure of the Anticoagulant Therapy and Psychological Distress: Still Far From a Bridge. Front Psychol 2018;9:1709. [PMID: 30271365 DOI: 10.3389/fpsyg.2018.01709] [Reference Citation Analysis]
116 Black-Maier E, Piccini JP. Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? Heart 2017;103:807-8. [PMID: 28069637 DOI: 10.1136/heartjnl-2016-310540] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
117 Kawaji T, Shizuta S, Aizawa T, Yamagami S, Takeji Y, Yoshikawa Y, Kato M, Yokomatsu T, Miki S, Ono K, Kimura T. Renal function and outcomes in atrial fibrillation patients after catheter ablation. PLoS One 2020;15:e0241449. [PMID: 33166317 DOI: 10.1371/journal.pone.0241449] [Reference Citation Analysis]
118 Lip GY, Waldo AL, Ip J, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen M, Halperin JL; IMPACT Investigators. Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT). Am J Cardiol 2016;118:1680-4. [PMID: 27665206 DOI: 10.1016/j.amjcard.2016.08.047] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
119 Farjat AE, Virdone S, Thomas LE, Kakkar AK, Pieper KS, Piccini JP. The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries. Am Heart J 2021;243:110-21. [PMID: 34529945 DOI: 10.1016/j.ahj.2021.09.003] [Reference Citation Analysis]
120 Faircloth JM, Miner KM, Alsaied T, Nelson N, Ciambarella J, Mizuno T, Palumbo JS, Vinks AA, Veldtman GR. Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. J Thromb Thrombolysis 2017;44:38-47. [DOI: 10.1007/s11239-017-1499-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
121 Bernaitis N, Ching CK, Teo SC, Chen L, Badrick T, Davey AK, Crilly J, Anoopkumar-Dukie S. Factors influencing warfarin control in Australia and Singapore. Thromb Res 2017;157:120-5. [PMID: 28738273 DOI: 10.1016/j.thromres.2017.07.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
122 Limdi NA, Brown TM, Shendre A, Liu N, Hill CE, Beasley TM. Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. Pharmacogenet Genomics 2017;27:347-55. [PMID: 28806200 DOI: 10.1097/FPC.0000000000000298] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
123 Yimer NS, Abiye AA, Hussen SU, Tadesse TA. Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia. Clin Appl Thromb Hemost 2021;27:10760296211049786. [PMID: 34724849 DOI: 10.1177/10760296211049786] [Reference Citation Analysis]
124 Pokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Reiffel JA, Singer DE, Freeman JV, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli GV, Ezekowitz MD, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiol 2019;4:756-64. [PMID: 31268487 DOI: 10.1001/jamacardio.2019.1960] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
125 Smetana KS, Dunne J, Parrott K, Davis GA, Collier ACS, Covell M, Smyth S. Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. J Thromb Thrombolysis 2017;44:519-24. [DOI: 10.1007/s11239-017-1560-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
126 Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip GYH; AFCAS Study Group. Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clin Res Cardiol 2017;106:420-7. [PMID: 28078448 DOI: 10.1007/s00392-016-1071-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
127 Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. J Thromb Haemost. 2018;16:1069-1077. [PMID: 29573330 DOI: 10.1111/jth.14007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
128 Eriksson N, Wallentin L, Berglund L, Axelsson T, Connolly S, Eikelboom J, Ezekowitz M, Oldgren J, Paré G, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Yusuf S, Wadelius M. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics 2016;17:1425-39. [PMID: 27488176 DOI: 10.2217/pgs-2016-0061] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]